Spots Global Cancer Trial Database for advanced breast carcinoma

Every month we try and update this database with for advanced breast carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors	NCT04541225	Glioma Glioma, Maligna... Glioma, Mixed Glial Cell Tumo... Breast Cancer Breast Carcinom... Cancer of Breas... Cancer of the B... Breast Tumor Malignant Tumor... Advanced Breast... Advanced Breast... Metastatic Brea... Metastatic Brea... Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration-resi... Castration Resi... Glioblastoma Recurrent Gliob...	NUV-422	18 Years -	Nuvation Bio Inc.
Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer	NCT02474173	Advanced Breast... Metastatic Brea... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Triple-Negative...	Laboratory Biom... Onalespib Paclitaxel Pharmacological...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	NCT04704661	Advanced Breast... Advanced Colon ... Advanced Colore... Advanced Endome... Advanced Gastri... Advanced Gastro... Advanced Malign... Advanced Saliva... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... HER2-Positive B... Malignant Hepat... Metastatic Brea... Metastatic Gast... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Colon... Stage III Color... Stage III Major... Stage III Uteri... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Uter... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Colon ... Stage IV Colore... Stage IV Major ... Stage IV Uterin... Stage IVA Colon... Stage IVA Color... Stage IVA Major... Stage IVA Uteri... Stage IVB Colon... Stage IVB Color... Stage IVB Major... Stage IVB Uteri... Stage IVC Colon... Stage IVC Color... Stage IVC Major... Unresectable Co... Unresectable Ga... Unresectable Ma...	Ceralasertib Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer	NCT04491942	Advanced Bile D... Advanced Breast... Advanced Cervic... Advanced Endome... Advanced Esopha... Advanced Gastri... Advanced Head a... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Ovaria... Advanced Penile... Advanced Pleura... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Stage III Cervi... Stage III Dista... Stage III Intra... Stage III Lung ... Stage III Ovari... Stage III Penil... Stage III Pleur... Stage IV Cervic... Stage IV Distal... Stage IV Intrah... Stage IV Lung C... Stage IV Ovaria... Stage IV Penile... Stage IV Pleura... Triple-Negative... Unresectable Ur...	Cisplatin Elimusertib Gemcitabine Hyd...	18 Years -	National Cancer Institute (NCI)
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	NCT05092373	Advanced Breast... Advanced Endome... Advanced Fallop... Advanced Hepato... Advanced Malign... Advanced Malign... Advanced Malign... Advanced Ovaria... Advanced Primar... Advanced Renal ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Malignant Abdom... Malignant Solid... Metastatic Brea... Metastatic Endo... Metastatic Fall... Metastatic Hepa... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Metastatic Rena... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Fallo... Stage III Hepat... Stage III Ovari... Stage III Prima... Stage III Renal... Stage III Uteri... Stage IIIA Fall... Stage IIIA Hepa... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Hepa... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Fallop... Stage IV Hepato... Stage IV Ovaria... Stage IV Primar... Stage IV Renal ... Stage IV Uterin... Stage IVA Fallo... Stage IVA Hepat... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVB Fallo... Stage IVB Hepat... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Atezolizumab Cabozantinib S-... Nab-paclitaxel Tumor Treating ...	18 Years -	M.D. Anderson Cancer Center
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	NCT03218826	Advanced Breast... Advanced Malign... Advanced Prosta... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Metastatic Brea... Metastatic Mali... Metastatic Pros... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... Triple-Negative... Unresectable So...	Docetaxel Laboratory Biom... Pharmacological... PI3Kbeta Inhibi...	18 Years -	National Cancer Institute (NCI)
Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer	NCT02270372	Advanced Breast... Advanced Ovaria...	ONT-10, Varlilu...	18 Years -	Seagen Inc.
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors	NCT04541225	Glioma Glioma, Maligna... Glioma, Mixed Glial Cell Tumo... Breast Cancer Breast Carcinom... Cancer of Breas... Cancer of the B... Breast Tumor Malignant Tumor... Advanced Breast... Advanced Breast... Metastatic Brea... Metastatic Brea... Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration-resi... Castration Resi... Glioblastoma Recurrent Gliob...	NUV-422	18 Years -	Nuvation Bio Inc.
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer	NCT03179904	Advanced Breast... HER2-Positive B... Anatomic Stage ... Anatomic Stage ... HER2-positive B...	Anastrozole Denifanstat Exemestane Fulvestrant Echocardiograph... Letrozole Paclitaxel Trastuzumab Computed Tomogr... Magnetic Resona... Biospecimen Col... Biopsy	18 Years -	Mayo Clinic
Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer	NCT06243432	Advanced Breast...		18 Years -	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer	NCT02270372	Advanced Breast... Advanced Ovaria...	ONT-10, Varlilu...	18 Years -	Seagen Inc.
SMMART Adaptive Clinical Treatment (ACT) Trial	NCT05238831	Advanced Breast... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Prosta... Advanced Sarcom... Anatomic Stage ... Anatomic Stage ... Recurrent Adult... Recurrent Breas... Recurrent Ovari... Recurrent Prost... Stage II Pancre... Stage III Ovari... Stage III Pancr... Stage IV Ovaria... Stage IV Pancre...	Alectinib Alpelisib Anastrozole Atezolizumab Bevacizumab Biopsy Biospecimen Col... Capecitabine Carboplatin Cobimetinib Entrectinib Eribulin Fulvestrant Hyaluronidase-z... Irinotecan Letrozole Nab-paclitaxel Niraparib Olaparib Paclitaxel Palbociclib Pertuzumab Quality-of-Life... Trastuzumab Trastuzumab Emt... Vemurafenib Vinorelbine Vismodegib	18 Years -	OHSU Knight Cancer Institute
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer	NCT03179904	Advanced Breast... HER2-Positive B... Anatomic Stage ... Anatomic Stage ... HER2-positive B...	Anastrozole Denifanstat Exemestane Fulvestrant Echocardiograph... Letrozole Paclitaxel Trastuzumab Computed Tomogr... Magnetic Resona... Biospecimen Col... Biopsy	18 Years -	Mayo Clinic
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer	NCT05969860	Advanced Anal C... Advanced Biliar... Advanced Bladde... Advanced Breast... Advanced Carcin... Advanced Cervic... Advanced Colore... Advanced Gastri... Advanced Gliobl... Advanced Head a... Advanced HER2 P... Advanced Lung C... Advanced Lung S... Advanced Malign... Advanced Malign... Advanced Neuroe... Advanced Ovaria... Advanced Pancre... Advanced Prosta... Advanced Prosta... Hematopoietic a... Multiple Myelom... Myelodysplastic...	Clinical Encoun... Home Health Enc... Quality-of-Life... Questionnaire A...	18 Years -	Mayo Clinic

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: